Prevest Denpro Ltd

Prevest Denpro Summary Chart Analysis Peers Quarters Profit & Loss Balance Sheet Cash Flow Ratios Investors Documents

Prevest Denpro Ltd

₹ 603 1.27%
09 Sep - close price
prevestdenpro.com BSE - SME: 543363
About

Incorporated in 2000, Prevest DenPro Limited is into development and manufacturing of dental materials used for diagnosis, prevention and treatment of dental conditions. Company is heavily export-oriented.

Key Points

Product Portfolio
Company manufactures over 100 dental products which comprise of:
a) Clinical Products: Adhesives, Bonding Agents & Etchants, Auxiliaries, Cement and Liners, Composites, Endodontics, Finishing & Polishing, Impression Materials, Oral Care, Orthodontics, Retraction Materials, Temporaries, and Tooth Whitening. [1]
b) Laboratory Products: Acrylics, Auxiliaries, Base Plates & Waxes, and Gypsum Products. [2]
Marquee Product - Resins: Company is the leading manufacturer of high-quality 3D printing resins designed for fabrication of dental crowns, bridges, inlays, onlays, and veneers. It offers several advantages over traditional fabrication methods.[3]
** Hygiene & Disinfectant** : This product is specifically formulated to combat a broad spectrum of pathogens, including bacteria, viruses, and fungi. These products are designed to target high-touch surfaces, medical devices, and equipment.[4]

Product Application
Their dental products find application in endodontics, prosthodontics, orthodontics, periodontics, restorative dentistry, aesthetic dentistry and for fabrication of prosthesis in dental laboratories. [5]
Prevest Denpro Limited operates with a business model focused on the manufacturing and distribution of dental materials and equipment.[6]

Website BSE
  • Market Cap ₹ 723 Cr.
  • Current Price ₹ 603
  • High / Low ₹ 673 / 332
  • Stock P/E 46.1
  • Book Value ₹ 73.8
  • Dividend Yield 0.17 %
  • ROCE 26.8 %
  • ROE 20.0 %
  • Face Value ₹ 10.0
Edit ratios

Pros

  • Company is almost debt free.
  • Company has delivered good profit growth of 40.1% CAGR over last 5 years
  • Company has a good return on equity (ROE) track record: 3 Years ROE 23.4%

Cons

  • Stock is trading at 8.16 times its book value
  • Debtor days have increased from 35.5 to 52.8 days.

* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.

Peer comparison

Sector: Healthcare Industry: Healthcare

Edit Columns
Loading peers table ...

Quarterly Results

Standalone Figures in Rs. Crores / View Consolidated

Dec 2021 Mar 2022 Jun 2022 Sep 2022 Dec 2022 Mar 2023 Jun 2023 Sep 2023 Dec 2023 Mar 2024 Jun 2024
11.41 9.33 12.37 11.45 12.27 13.77 13.39 13.18 13.62 16.24 13.34
6.52 6.42 7.80 7.00 7.30 8.16 8.43 8.68 9.15 10.36 8.85
Operating Profit 4.89 2.91 4.57 4.45 4.97 5.61 4.96 4.50 4.47 5.88 4.49
OPM % 42.86% 31.19% 36.94% 38.86% 40.51% 40.74% 37.04% 34.14% 32.82% 36.21% 33.66%
0.38 0.86 0.62 0.58 0.50 0.33 0.61 0.74 0.68 0.84 0.86
Interest 0.02 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Depreciation 0.13 0.15 0.15 0.19 0.18 0.16 0.17 0.22 0.42 0.46 0.48
Profit before tax 5.12 3.62 5.04 4.84 5.29 5.78 5.40 5.02 4.73 6.26 4.87
Tax % 26.76% 32.04% 27.18% 31.20% 31.95% 11.76% 24.26% 25.70% 23.26% 25.56% 25.26%
3.75 2.46 3.68 3.33 3.59 5.11 4.08 3.74 3.64 4.66 3.65
EPS in Rs 3.12 2.05 3.07 2.77 2.99 4.26 3.40 3.12 3.03 3.88 3.04
Raw PDF

Profit & Loss

Standalone Figures in Rs. Crores / View Consolidated

Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 TTM
19 23 28 38 50 56 56
15 17 19 23 30 36 37
Operating Profit 4 5 9 15 20 20 19
OPM % 20% 23% 32% 40% 40% 36% 34%
0 2 1 2 2 3 3
Interest 0 0 0 0 0 0 0
Depreciation 0 0 0 1 1 1 2
Profit before tax 4 6 9 16 21 21 21
Tax % 20% 20% 23% 28% 25% 25%
3 5 7 12 16 16 16
EPS in Rs 1,049.12 1,757.89 252.98 9.64 13.09 13.43 13.07
Dividend Payout % 0% 0% 0% 0% 8% 7%
Compounded Sales Growth
10 Years: %
5 Years: 24%
3 Years: 26%
TTM: 11%
Compounded Profit Growth
10 Years: %
5 Years: 40%
3 Years: 31%
TTM: -3%
Stock Price CAGR
10 Years: %
5 Years: %
3 Years: %
1 Year: 26%
Return on Equity
10 Years: %
5 Years: 26%
3 Years: 23%
Last Year: 20%

Balance Sheet

Standalone Figures in Rs. Crores / View Consolidated

Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024
Equity Capital 0 0 0 12 12 12
Reserves 10 15 22 45 61 77
1 2 1 1 0 0
4 4 7 6 6 6
Total Liabilities 15 21 31 64 79 95
5 5 5 7 7 27
CWIP 0 0 2 5 17 0
Investments 0 0 0 1 1 2
10 16 23 52 53 66
Total Assets 15 21 31 64 79 95

Cash Flows

Standalone Figures in Rs. Crores / View Consolidated

Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024
3 5 9 7 11 11
-1 -1 -2 -4 -13 -2
0 0 -1 23 -1 -0
Net Cash Flow 2 4 6 26 -3 9

Ratios

Standalone Figures in Rs. Crores / View Consolidated

Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024
Debtor Days 46 35 48 22 31 53
Inventory Days 28 59 59 122 139 162
Days Payable 70 72 181 61 40 34
Cash Conversion Cycle 4 22 -74 83 130 181
Working Capital Days 10 20 3 41 64 80
ROCE % 45% 47% 40% 32% 27%

Shareholding Pattern

Numbers in percentages

Sep 2021Mar 2022Jun 2022Sep 2022Dec 2022Mar 2023Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024
73.60% 73.60% 73.60% 73.60% 73.60% 73.60% 73.60% 73.60% 73.60% 73.60% 73.60%
4.63% 0.76% 0.66% 0.47% 0.21% 0.30% 0.26% 0.31% 0.31% 0.52% 1.11%
4.37% 1.24% 1.19% 1.16% 0.95% 0.95% 0.61% 0.71% 0.68% 0.68% 0.68%
17.40% 24.40% 24.55% 24.76% 25.24% 25.14% 25.53% 25.37% 25.40% 25.20% 24.61%
No. of Shareholders 5161,0031,2561,4961,5441,6131,7581,9372,0401,9911,896

* The classifications might have changed from Sep'2022 onwards. The new XBRL format added more details from Sep'22 onwards.

Classifications such as banks and foreign portfolio investors were not available earlier. The sudden changes in FII or DII can be because of these changes.

Click on the line-items to see the names of individual entities.

Documents

Announcements

Annual reports

Concalls